Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05993195 · ClinicalTrials.gov registry record

Re-operation Rates of Concorde Bullet Device Versus Conduit Titanium Interbody Graft for Lumbar Fusion

A clinical trial of Degenerative Spondylolisthesis and Lumbar Spondylosis, sponsored by Lahey Clinic.

Completed
Registry status
100
Enrollment target
1
Study location

NCT05993195 is a study of Degenerative Spondylolisthesis and Lumbar Spondylosis that has completed, run by Lahey Clinic. The registered enrollment target is 100 participants, below the 262-participant average among 5 other Degenerative Spondylolisthesis trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05993195, a study of Degenerative Spondylolisthesis and Lumbar Spondylosis, has completed, sponsored by Lahey Clinic.

COMPLETED
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this early study is to compare the clinical results of the new Conduit Interbody device to the traditional Concorde Bullet Device. The primary objective is to explore the rates and reasons for re-operation between both constructs at 2 years.

Interventions

  • DEVICE Conduit Titanium Interbody Graft
  • DEVICE Concorde Bullet Device

Study Locations (1)

Massachusetts

  • Lahey Hospital and Medical Center - Burlington

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-03-12
Est. Completion 2024-03-31

Sponsor

Lahey Clinic

43 total trials

What the Registry Record Tells You About NCT05993195

The ClinicalTrials.gov registry entry for NCT05993195 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 5 other Degenerative Spondylolisthesis trials with a reported enrollment target (62% lower). The listed sponsor is Lahey Clinic, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Degenerative Spondylolisthesis appearing as the primary indexed condition, and to 2 interventions - of which Conduit Titanium Interbody Graft is the first listed.

NCT05993195 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05993195 about?

NCT05993195 is a clinical study titled "Re-operation Rates of Concorde Bullet Device Versus Conduit Titanium Interbody Graft for Lumbar Fusion". The purpose of this early study is to compare the clinical results of the new Conduit Interbody device to the traditional Concorde Bullet Device. The primary objective is to explore the rates and reasons for re-operation between both constructs at 2 years.

What is the current status of trial NCT05993195?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2021-03-12. Estimated completion is 2024-03-31.

What conditions does trial NCT05993195 study?

This clinical trial studies the following conditions: Degenerative Spondylolisthesis, Lumbar Spondylosis, Lumbar Spondylolisthesis.

What interventions are being tested in trial NCT05993195?

The interventions under investigation include: Conduit Titanium Interbody Graft (DEVICE), Concorde Bullet Device (DEVICE).

Who is sponsoring clinical trial NCT05993195?

This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05993195 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Degenerative Spondylolisthesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.